Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

Trump's return to the White House has introduced significant uncertainty for investors in the medical device industry. Major ...

President Donald Trump has swiftly announced a series of executive orders that could impact the medech industry.

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

Johnson & Johnson (J&J) MedTech has reported a 4.8% growth in global sales in 2024, though it expects its 2025 outlook to ...

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

In diabetes care, the MiniMed 780G insulin pump system uses AI algorithms to predict and adjust insulin delivery based on ...

The MLV100 2025 Yearbook, featuring 100 MedTech Leading Voices worth following on LinkedIn in 2025, has just been released. This hand-curated guide highlights leaders worldwide who consistently ...

FORT WORTH, TX - Sanara MedTech Inc. (NASDAQ:SMTI), a medical technology company with a market capitalization of $294 million, announced the appointment of Elizabeth Taylor as Chief Financial Officer ...

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

OncoAssure's new data demonstrates that its biopsy test provides an 'improved estimation' of a patient’s risk of prostate ...

Corilus connects healthcare providers, patients and stakeholders via its cloud-based software and patient app.